Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Gleave

Showing results (21-30 of 258) with videos related to

Pageof 26
Sort By:
Urologic Oncology|December 30, 2008
The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancerMartin Gleave, Laurence Klotz, Samir S Taneja
Targeted Oncology|August 16, 2016
Effect of Targeting Clusterin Using OGX-011 on Antitumor Activity of Temsirolimus in a Human Renal Cell Carcinoma ModelMasatomo Nishikawa, Hideaki Miyake, Martin Gleave, et al.
Current Genomics|July 23, 2008
The role of stress proteins in prostate cancerAlan So, Boris Hadaschik, Richard Sowery, et al.
Urology|January 18, 2002
Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrenceHideaki Miyake, Martin Gleave, Sadao Kamidono, et al.
World Journal of Urology|March 17, 2005
Mechanisms of the development of androgen independence in prostate cancerAlan So, Martin Gleave, Antonio Hurtado-Col, et al.
Cancer Causes & Control : CCC|September 27, 2005
Intake of selenium in the prevention of prostate cancer: a systematic review and meta-analysisMahyar Etminan, J Mark FitzGerald, Martin Gleave, et al.
Cancer Metastasis Reviews|October 29, 2002
Antisense therapy: current status in prostate cancer and other malignanciesMartin Gleave, Hideake Miyake, Uwe Zangemeister-Wittke, et al.
The Canadian Journal of Urology|May 30, 2003
Intermittent androgen suppression in prostate cancer: an update of the Vancouver experienceMichael Pether, S Larry Goldenberg, Kapil Bhagirath, et al.
Molecular Cancer Therapeutics|December 24, 2005
Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivoAlan So, Shannon Sinnemann, David Huntsman, et al.
EMBO Molecular Medicine|August 4, 2025
New frontiers in prostate cancer treatment from systemic therapy to targeted therapyShaghayegh Nouruzi, Maxim Kobelev, Nakisa Tabrizian, et al.
Pageof 26

Showing results (21-30 of 258) with videos related to

Sort By:
Pageof 26
Urologic Oncology|December 30, 2008
The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancerMartin Gleave, Laurence Klotz, Samir S Taneja
Targeted Oncology|August 16, 2016
Effect of Targeting Clusterin Using OGX-011 on Antitumor Activity of Temsirolimus in a Human Renal Cell Carcinoma ModelMasatomo Nishikawa, Hideaki Miyake, Martin Gleave, et al.
Current Genomics|July 23, 2008
The role of stress proteins in prostate cancerAlan So, Boris Hadaschik, Richard Sowery, et al.
Urology|January 18, 2002
Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrenceHideaki Miyake, Martin Gleave, Sadao Kamidono, et al.
World Journal of Urology|March 17, 2005
Mechanisms of the development of androgen independence in prostate cancerAlan So, Martin Gleave, Antonio Hurtado-Col, et al.
Cancer Causes & Control : CCC|September 27, 2005
Intake of selenium in the prevention of prostate cancer: a systematic review and meta-analysisMahyar Etminan, J Mark FitzGerald, Martin Gleave, et al.
Cancer Metastasis Reviews|October 29, 2002
Antisense therapy: current status in prostate cancer and other malignanciesMartin Gleave, Hideake Miyake, Uwe Zangemeister-Wittke, et al.
The Canadian Journal of Urology|May 30, 2003
Intermittent androgen suppression in prostate cancer: an update of the Vancouver experienceMichael Pether, S Larry Goldenberg, Kapil Bhagirath, et al.
Molecular Cancer Therapeutics|December 24, 2005
Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivoAlan So, Shannon Sinnemann, David Huntsman, et al.
EMBO Molecular Medicine|August 4, 2025
New frontiers in prostate cancer treatment from systemic therapy to targeted therapyShaghayegh Nouruzi, Maxim Kobelev, Nakisa Tabrizian, et al.
Pageof 26